Gujarat Themis Biosyn Announces Special Window for Share Transfer & Dematerialization
Gujarat Themis Biosyn opens a one-year special window (Feb 5, 2026 - Feb 4, 2027) for dematerializing physical shares and re-lodging transfer requests for shares transacted before April 1, 2019. This complies with a SEBI circular to regularize pending transfer cases.
This is a routine regulatory compliance announcement providing a facility for a specific group of shareholders. It does not have a direct material impact on the company's operations, financials, or stock price.
The announcement is a regulatory compliance notification regarding a special window for share transfers and dematerialization. It does not contain financial results or strategic business updates that would indicate a positive or negative sentiment.
Gujarat Themis Biosyn Limited has announced a special window for the re-lodgement of transfer requests and dematerialization of physical shares. This facility is available for a period of one year, from February 05, 2026, to February 04, 2027, in compliance with SEBI Circular No. HD/38/13/11(2)2026-MIRSDPOD/1/3750/2026 dated January 30, 2026.
The special window is for shareholders who sold or purchased shares before April 01, 2019, and either had not lodged the shares for transfer or had lodged them but they were rejected or returned due to deficiencies. Requests must be accompanied by original share certificates and transfer deeds. Shares transferred under this window will be credited only in Demat mode and will be under a one-year lock-in period from the date of registration of transfer, during which they cannot be transferred, lien-marked, or pledged.
Investors wishing to utilize this facility can contact the Company's Registrar & Transfer Agent, MUFG Intime India Private Limited. The company encourages investors to take necessary actions promptly to regularize pending transfer cases. This announcement was published in 'Western Times' (English and Gujarati editions) on April 8, 2026.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.